Table 1 Patient characteristics at first measurement of DLCO < 50% of predicted
From: Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis
|  | n = 106 | |
|---|---|---|
Age | 49 ± 13 years | |
Male/Female | 72 (68)/34 (32) | |
White/ Non-white/Unknown | 66 (62)/30 (28)/10 (9) | |
Histologic confirmation | 104 (98) | |
Smoking history | Never | 29 (27) |
Former | 48 (45) | |
Current | 23 (22) | |
Unknown | 6 (6) | |
Cardiac involvement | Probable | 6 (6) |
Possible | 2 (2) | |
 ≥ 2 organs involved | 95 (90) | |
Therapy | Corticosteroids | 59 (56) |
Methotrexate | 37 (35) | |
Azathioprine | 3 (3) | |
Plaquenil | 4 (4) | |
Anti-TNF treatment | 8 (8) | |
None | 26 (25) | |
Unknown | 4 (4) | |
Duration of disease prior to baseline time point | 5 (13) years | |
Scadding stage | 0 | 2 (2) |
I | 4 (4) | |
II | 19 (18) | |
III | 12 (11) | |
IV | 63 (59) | |
Unknown | 6 (6) | |
PH | Diagnosed with RHC | 9 (8) |
PH suspected on echocardiogram | 3 (3) | |
FVC % predicted | 70 ± 17 | |
FEV1% predicted | 60 ± 18 | |
DLCOc% predicted | 42 ± 7 | |
CPI | 47 ± 9 | |
Walsh poor prognosis | 98 (92) | |
MUC5B promotor polymorphism | GG | 83 (78) |
GT | 23 (22) | |
TT | 0 | |